Could less chemo be enough? new trial aims to treat High-Risk neuroblastoma with reduced therapy
NCT ID NCT06528496
First seen Jun 27, 2026 · Last updated Jul 23, 2026 · Updated 2 times
Summary
This phase 2 trial is testing whether a reduced chemotherapy regimen called N10 is safe and effective for children with high-risk neuroblastoma. The study will enroll 45 children under 19 years old who have not had more than one prior chemo cycle. The goal is to see if this lighter approach can still achieve a complete response while potentially causing fewer side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- N10 chemotherapy (naxitamab, sargramostim, cyclophosphamide, topotecan, vincristine)
- What this could lead to
- If successful, this could lead to a less intensive treatment option for children with high-risk neuroblastoma, potentially reducing side effects while maintaining effectiveness.
- What could go wrong
- This is a small, early-phase trial with only 45 participants, so results may not apply to all patients. The reduced therapy might be less effective or still cause significant side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHILDHOOD NEUROBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10065, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A simple blood test may reveal hidden infertility risk in young cancer survivors
- Can a shorter chemo combo tame High-Risk neuroblastoma?
- Can a radioactive 'Smart Bomb' take down resistant childhood cancers?
- Can AI read tumor slides to outsmart childhood cancer?
- Can a radioated molecule shrink untreatable neuroblastoma?
- Slowing down immunotherapy infusion may reduce pain in children with Tough-to-Treat neuroblastoma